This theoretical article revives a classical bridging construct, canalization, to describe a new
model of a general factor of psychopathology. To achieve this, we have distinguished …

… Author links open overlay panel Marco Aqil a b c , Leor Roseman d … to those recorded during
the viewing of spatially localised stimuli (Roseman et al., 2016), and increased BOLD signal …

Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the
human brain have never been studied before with modern neuroimaging. Here, three …

… } {A_{ijl}}\) is the total FC of layer l, A ijl is the FC between ROI i and j at layer l, \(\frac{{k_{il}k_{jl}}}{{2m_l}}\)
is the expected null FC at layer l. The two free γ and ω structural and temporal …

Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the
acute experience mediates long-term improvements in mental health. In the present paper …

Psilocybin with psychological support is showing promise as a treatment model in psychiatry
but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and …

Psychedelics have attracted medical interest, but their effects on human brain function are
incompletely understood. In a comprehensive, within-subjects, placebo-controlled design, we …

Psychedelic therapy has witnessed a resurgence in interest in the last decade from the
scientific and medical communities with evidence now building for its safety and efficacy in …

Psychedelic drugs are making waves as modern trials support their therapeutic potential and
various media continue to pique public interest. In this opinion piece, we draw attention to a …

Lysergic acid diethylamide (LSD) is a non-selective serotonin-receptor agonist that was first
synthesized in 1938 and identified as (potently) psychoactive in 1943. Psychedelics have …